Tarsus Pharmaceuticals Inc (NASDAQ: TARS) — Company Overview, News & Financial Data
Tarsus Pharmaceuticals focuses on innovative therapies for eye conditions, targeting significant unmet medical needs in ocular health.
Tarsus Pharmaceuticals Inc
Tarsus Pharmaceuticals (NASDAQ:TARS) is a biopharmaceutical company focused on the development and commercialization of innovative therapies for a variety of eye conditions. The company works on breakthrough treatments aimed at addressing significant unmet medical needs in ocular health. Among its key projects is the development of a pioneering solution for Demodex blepharitis, a common eyelid condition that Tarsus is targeting with its flagship drug candidate. This initiative highlights the company's commitment to transforming patient care in ophthalmology. Additionally, Tarsus Pharmaceuticals explores treatments for other eye diseases, underscoring its objective to become a leader in eye care solutions by delivering novel and effective therapies to patients worldwide.
Snapshot
Operations
Products and/or services of Tarsus Pharmaceuticals Inc
- TP-03 (lotilaner ophthalmic solution, 0.25%) is designed to treat Demodex blepharitis, a common eyelid margin disease.
- Zerym (formerly TP-03) targets the elimination of Demodex mites, aiming to address the root cause of Demodex blepharitis.
- TP-04 is being developed to treat Rosacea, focusing on the inflammatory and erythematous components of the condition.
- TP-05 is an oral formulation aimed at Lyme disease prevention, targeting the reduction of Lyme disease incidence post-tick bite.
Tarsus Pharmaceuticals Inc executive team
- Bobak R. AzamianCo-Founder, President, CEO & Chairman
- Jeffrey S. FarrowCFO & Chief Strategy Officer
- Seshadri NeervannanChief Operating Officer
- Bryan WahlGeneral Counsel & Corporate Secretary
- David NakasoneHead of Investor Relations
- Adrienne KempVice President of Corporate Communications
- Matthew RossenVice President of Marketing
- Scott YoumansVice President of Sales
- Dianne C. WhitfieldChief Human Resources Officer
- Elizabeth Yeu-LinChief Medical Officer
Latest news about Tarsus Pharmaceuticals Inc
Key financials
Reported results for Tarsus Pharmaceuticals Inc, in USD.
- Market cap
- 3.5B
- Revenue (TTM)
- 606.3M
- P/E ratio
- —
- EPS (diluted, TTM)
- -1.1
- Dividend yield
- —
- Profit margin
- -7.7%
| Fiscal year end | Revenue | Operating income | Net income |
|---|---|---|---|
| 451.4M | -71M | -66.4M | |
| 183M | -120.6M | -115.6M | |
| 17.4M | -143.2M | -135.9M | |
| 25.8M | -62.7M | -62.1M |